Evidence map›Paper›PMID 39633174›Full record

ArticleAnnals of surgical oncology2025

Propensity Score-Matched Analysis of Liver Venous Deprivation and Portal Vein Embolization Before Planned Hepatectomy in Patients with Extensive Colorectal Liver Metastases and High-Risk Factors for Inadequate Regeneration.

Antony Haddad, Mohammad Mahdi Khavandi, Mateo Lendoire, Belkacem Acidi, Yi-Ju Chiang, Sanjay Gupta, Alda Tam, Bruno C Odisio, Armeen Mahvash, Mohamed E Abdelsalam and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Antony Haddad *Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohammad Mahdi Khavandi *Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mateo LendoireDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Belkacem AcidiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yi-Ju ChiangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sanjay GuptaDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alda TamDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bruno C OdisioDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Armeen MahvashDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohamed E AbdelsalamDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan LinDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joshua KubanDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy E NewhookDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hop S Tran CaoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven Y HuangDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jean-Nicolas Vauthey *Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jvauthey@mdanderson.org.
Peiman Habibollahi *Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PHabibollahi@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver venous deprivation (LVD) is known to induce better future liver remnant (FLR) hypertrophy than portal vein embolization (PVE). The role of LVD, compared with PVE, in inducing FLR hypertrophy and allowing safe hepatectomy for patients with extensive colorectal liver metastases (CLM) and high-risk factors for inadequate hypertrophy remains unclear.

methodsPatients undergoing LVD (n = 22) were matched to patients undergoing PVE (n = 279) in a 1:3 ratio based on propensity scores, prior to planned hepatectomy for CLM at a single center (1998-2023). The propensity scores accounted for high-risk factors for inadequate hypertrophy, namely pre-procedure standardized FLR (sFLR), body mass index, number of systemic therapy cycles, an extension of PVE to segment IV portal vein branches, prior resection, and chemotherapy-associated liver injury.

resultsThe matched cohort included 78 patients (LVD, n = 22; PVE, n = 56). Baseline characteristics were comparable. The number of tumors in the whole liver was similar but more LVD patients had five or more tumors in the left liver (32% vs. 11%; p = 0.024). Post-procedure sFLR was similar but LVD patients had a significantly higher degree of hypertrophy (16% vs. 11%; p = 0.017) and kinetic growth rate (3.9 vs. 2.4% per week; p = 0.006). More LVD patients underwent extended right hepatectomy (93% vs. 55%; p = 0.008). Only one patient had postoperative hepatic insufficiency after PVE, and no patients died within 90 days of hepatectomy.

conclusionIn patients with extensive CLM and high-risk factors, LVD is associated with better FLR hypertrophy compared with PVE and allows for safely performing curative-intent extended major hepatectomy.

Indexed as

Colorectal NeoplasmsEmbolization, TherapeuticHepatectomyHepatic VeinsLiver NeoplasmsLiver RegenerationPortal VeinAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisPropensity ScoreRetrospective Studies

Identifiers

PMID39633174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.